21.04.17 - The Bill & Melinda Gates foundation has awarded EPFL-based non-profit iM4TB $2.45 million to take their innovative anti-tuberculosis drug PBTZ169 into clinical trials.

07.07.15 - Testing thousands of approved drugs, EPFL scientists have identified an unlikely anti-tuberculosis drug: the over-the-counter antacid lansoprazole (Prevacid^®).

12.03.14 - Even though tuberculosis kills more than 1.5 million people every year, the market is not cost-effective for pharmaceutical companies. So EPFL is setting up a foundation to release an antibiotic developed in its own laboratories under EU funding.